Peripheral Mechanisms of Humoral Immune Effector-mediated Tourette's Syndrome and the Role of Tuina Intervention

Launched by THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY · Apr 18, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how the immune system might play a role in Tourette syndrome (TS) in children and whether a traditional Chinese therapy called Tuina can help improve symptoms. Researchers believe that certain immune factors and food intolerances may contribute to TS, and they want to see if children with TS show different levels of these immune factors compared to healthy children. By studying these differences, the trial aims to understand how Tuina might help reduce tics by affecting the levels of inflammation and immune response in the body.

To be eligible for this trial, participants should be outpatients diagnosed with Tourette syndrome who have not taken specific medications that could interfere with the study for at least a month. Children with severe tics or other serious health conditions are not eligible. If accepted, participants will undergo various assessments to track their symptoms and health throughout the study. This research could lead to new insights and treatment options for children with Tourette syndrome, making it an important step in understanding and managing this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Outpatients who meet the diagnostic criteria for TS；
• • Haven't taken any drugs that affect the efficacy evaluation, such as antipsychotic drugs or traditional Chinese medicines with similar effects, or have received treatment but have passed the drug washout period for more than 1 month before enrollment；
• • The legal guardian and the subject themselves have been informed consent, and have signed the informed consent form, agreeing to participate in this trial, and have been reviewed and approved by the Ethics Committee of Zhejiang Provincial Hospital of Traditional Chinese Medicine.
• Exclusion Criteria:
• • Any chorenia, Wilson's disease, epileptic myoclonus, drug-induced extrapyramidal symptoms and other extrapyramidal diseases;
• • A history of severe tics;
• • Any primary diseases such as cardiovascular, hepatic, renal and hematopoietic systems;
• • Allergic or allergic to the drug in this test;
• • Current taking other drugs or accept other treatments at the same time affect the evaluation of efficacy